Pubblicazioni

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo

2024 - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Guttman-Yassky, E.; Del Duca, E.; Da Rosa, J. C.; Bar, J.; Ezzedine, K.; Ye, Z.; He, W.; Hyde, C.; Hassan-Zahraee, M.; Yamaguchi, Y.; Peeva, E.

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

2022 - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Guttman-Yassky, E.; Pavel, A. B.; Diaz, A.; Zhang, N.; Del Duca, E.; Estrada, Y.; King, B.; Banerjee, A.; Banfield, C.; Cox, L. A.; Dowty, M. E.; Page, K.; Vincent, M. S.; Zhang, W.; Zhu, L.; Peeva, E.